SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Sangamo Therapeutics, Inc.

501 Canal Boulevard
Richmond, CA 94804
United States
510-970-6000
http://www.sangamo.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees131

Key Executives

NameTitlePayExercisedAge
Dr. Alexander D. Macrae M.B., Ch.B, Ph.D., MRCPPres, CEO & Director697kN/A54
Mr. Curt A. Herberts IIISr. VP & Chief Bus. Officer362.26kN/A36
Dr. Edward R. Conner M.D.Sr. VP & Chief Medical Officer134.85kN/A44
Ms. Kathy Y. YiSr. VP & CFON/AN/A45
Dr. R. Andrew Ramelmeier Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company’s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington’s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.

Corporate Governance

Sangamo Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 2. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.